Lung Cancer Diagnostic Workup A-to-Z: Tests You'll Need
Share
From the first hint of a problem (a symptom, an incidental finding, or an abnormal screen) to a treatment-ready diagnosis takes a defined sequence of tests. Knowing the steps in advance helps patients move efficiently rather than discovering each new test as it's ordered. This article maps the full diagnostic pathway for suspected lung cancer — imaging, biopsy, molecular testing, staging — with costs at each step and how international self-pay patients can compress it.
Symptom or Screening Trigger
The workup begins with one of three triggers:
- Symptom-driven: persistent cough >3 weeks, hemoptysis, unexplained dyspnea, chest pain, weight loss, hoarseness
- Incidental finding: nodule discovered on a chest X-ray or CT done for other reasons (preoperative clearance, trauma, cardiac evaluation)
- Screening: LDCT in eligible smokers; rising tumor markers
Each trigger leads into the same diagnostic cascade, with slight variations in urgency.
Imaging Cascade: CXR → CT → PET-CT
Standard imaging progression:
Chest X-ray (CXR):
- Often the first test ordered for chest symptoms
- Cost: $50–150 US; ¥150–300 China
- Sensitivity for lung cancer: ~70% (misses ~30% of early disease)
Diagnostic chest CT (with or without contrast):
- Characterizes any lesion seen on X-ray
- Often added even if X-ray is negative when symptoms persist
- With contrast preferred for mediastinal evaluation
- Cost: $500–1,500 US (cash); ¥800–1,800 China
PET-CT (whole-body FDG):
- Ordered after confirmed or strongly suspected cancer on CT
- Stages distant disease and mediastinal nodes
- Cost: $3,500–6,500 US; ¥6,500–9,000 China
Brain MRI with contrast:
- Standard at staging for intermediate/high-risk lung cancer
- Detects brain metastases not visible on PET-CT
- Cost: $1,500–3,500 US; ¥900–1,800 China
Biopsy Options: Bronchoscopy, EBUS, CT-Guided
Tissue diagnosis is essential. The choice depends on lesion location and which mediastinal nodes need staging:
| Method | Best for | Sensitivity | US cost | China cost |
|---|---|---|---|---|
| CT-guided percutaneous biopsy | Peripheral lesion | 85–90% | $4,000–9,000 | ¥6,000–12,000 |
| Bronchoscopy with biopsy | Central, endobronchial | 70–80% | $3,000–6,000 | ¥4,000–8,000 |
| EBUS-TBNA | Mediastinal nodes | ~85% | $3,500–6,000 | ¥3,000–6,000 |
| Mediastinoscopy | Definitive node staging | ~95% | $8,000–15,000 | ¥10,000–25,000 |
| VATS wedge resection | Diagnostic + therapeutic | 95%+ | $25,000–50,000 | ¥35,000–60,000 |
Modern practice often combines techniques: a single bronchoscopy session can do EBUS-TBNA of multiple node stations plus transbronchial biopsy of the primary tumor.
Histology and Cell Type
Pathology distinguishes:
- Non-small cell lung cancer (NSCLC) — ~85% of lung cancer
- Adenocarcinoma — most common, especially in non-smokers and women
- Squamous cell carcinoma — historically associated with smoking
- Large cell carcinoma — less common
- Small cell lung cancer (SCLC) — ~15%; neuroendocrine origin; faster growth
Pathologists use immunohistochemistry to subtype (TTF-1, p40, synaptophysin, chromogranin A). The subtype determines:
- Whether molecular testing is needed
- Whether immunotherapy is appropriate
- Treatment regimen
- Prognosis
A diagnostic pathology report typically takes 5–10 business days. International patients can request slides and tissue blocks to send to a second-opinion pathologist back home or at a Chinese center.
Molecular and Genetic Testing
For non-squamous NSCLC (and increasingly squamous), comprehensive molecular testing is now standard before initiating treatment:
Single-gene tests (faster, lower-cost):
- EGFR mutation testing
- ALK rearrangement
- ROS1 rearrangement
- BRAF V600E
- KRAS G12C
- HER2 mutation
Comprehensive next-generation sequencing (NGS) panel:
- All of the above plus MET, RET, NTRK, NRG1, others
- Provides PD-L1 status if requested
- Cost: $2,500–4,500 US; ¥6,000–10,000 China (Burning Rock OncoLBP, Geneseeq, OrigiMed are major Chinese vendors)
Liquid biopsy (ctDNA) as alternative when tissue insufficient:
- Detects driver mutations from blood
- Cost: $4,500–7,500 US; ¥8,000–15,000 China
- Sensitivity in metastatic disease: ~70–85%
For molecular workup interpretation in your specific lung cancer case, our team can help.
PD-L1 Immunotherapy Markers
PD-L1 (Programmed Death Ligand 1) expression is measured by immunohistochemistry on the tumor biopsy. The Tumor Proportion Score (TPS):
- PD-L1 ≥50%: strong indication for first-line single-agent pembrolizumab (Keytruda)
- PD-L1 1–49%: combination chemo + immunotherapy preferred
- PD-L1 <1%: chemotherapy ± immunotherapy depending on regimen
The PD-L1 assay differs slightly between drug labels (PD-L1 22C3 for pembrolizumab, 28-8 for nivolumab, etc.), but the clinical interpretation is similar.
Cost of PD-L1 testing: typically bundled into the pathology workflow at no separate charge, or $200–500 US standalone.
Staging Investigations: Brain MRI, Bone Scan
Beyond PET-CT for body staging, additional tests for specific scenarios:
Brain MRI with contrast: standard at staging for any intermediate or high-risk lung cancer
- Detects asymptomatic brain metastases in 10–25% at diagnosis
- Cost: $1,500–3,500 US; ¥900–1,800 China
Bone scan or PET-CT: bone metastases
- PET-CT typically replaces bone scan for staging
- Cost: ¥2,500–4,000 China (bone scan alone)
Pleural fluid cytology (if effusion present): malignant cells confirm M1a stage
Bronchoalveolar lavage: in some lepidic/ground-glass cases
Cardiac assessment: before any major surgery; echo, sometimes stress test
Putting It Together: Time and Cost
A complete workup from CT discovery to treatment-ready diagnosis typically:
- In US/UK with conventional appointment scheduling: 4–8 weeks
- In US/UK with expedited cancer center pathway: 2–4 weeks
- In China with international patient bundled service: 5–10 business days
Approximate total costs:
| Component | US (insurance + copays) | US (cash) | China (top hospital cash) |
|---|---|---|---|
| Imaging (CT, PET, brain MRI) | $1,500–4,000 OOP | $5,500–11,500 | ¥8,500–13,000 |
| Biopsy + pathology | $500–2,500 OOP | $5,500–11,500 | ¥8,000–18,000 |
| Molecular testing (NGS) | $0–1,500 OOP | $2,500–4,500 | ¥6,000–10,000 |
| Multidisciplinary review | $200–800 OOP | $1,500–3,500 | ¥2,000–5,000 |
| Total workup | $2,200–8,800 OOP | $15,000–31,000 | ¥24,500–46,000 ($3,500–6,600) |
For self-pay patients (uninsured or with high-deductible plans), the China differential is substantial. Speed is also a major factor — workup in 5–10 days vs 4–8 weeks can be the difference in early treatment.
Frequently Asked Questions
Can I do all of this in one trip to China?
Yes. Top international patient services at PUMC Beijing, Sun Yat-sen Cancer Center, Fudan SCC, and Ruijin coordinate the full workup over 5–10 business days. The bottleneck is typically pathology turnaround (5–8 days) and NGS results (5–10 days).
Will my home oncologist work with Chinese workup reports?
Yes. Standards are international. DICOM imaging, pathology slides, and NGS reports are universally interpretable. Your home team can integrate findings and continue care.
Can I do part of the workup at home and part in China?
Common scenario. Patients often have imaging and biopsy at home, then bring slides and DICOM files for second opinion or treatment planning in China. Or vice versa — workup in China, treatment back home.
What if the biopsy doesn't yield enough tissue for molecular testing?
Liquid biopsy (ctDNA blood test) can substitute for missing tissue molecular data. Alternative: repeat biopsy.
Should I get a second pathology opinion?
For cases where treatment depends on subtype (small cell vs adenocarcinoma, for example), yes. Second-opinion pathology at top centers costs $200–500 US or ¥800–2,000 China.
Are there international standards for the workup sequence?
NCCN (US) and ESMO (Europe) guidelines are widely followed in Asia and represent the international standard. Top Chinese centers follow NCCN protocols.
Need Help Booking?
SinoCareLink can pre-book the complete diagnostic workup at a top Chinese cancer center, coordinate biopsy, molecular testing, multidisciplinary review, and treatment planning in 5–10 business days, translate reports into English, and arrange airport pickup. Contact us for a free consultation.